Treatment of Sjogren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study

Imagem de Miniatura
Arquivos
art_MOSCOVICI_Treatment_of_Sjogrens_syndrome_dry_eye_using_003_2015.PDF (515.24 KB)
Citações na Scopus
71
Tipo de produção
article
Data de publicação
2015
Editora
ELSEVIER SCIENCE BV
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
MOSCOVICI, Bernardo Kaplan
HOSHINO-RUIZ, Diego Ricardo
ALBERS, Marcos Bottene Villa
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CONTACT LENS & ANTERIOR EYE, v.38, n.5, p.373-378, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To describe the clinical efficacy of the treatment of Sjogren's syndrome dry eye using 0.03% tacrolimus eye drop. Design: Prospective double-blind randomized study. Setting: Institutional outpatient clinic. Participants: Forty-eight eyes of twenty-four patients with dry eye related to Sjogren syndrome were enrolled in this study. The patients were randomized in 2 groups: tacrolimus (n= 14) and vehicle (n=10) group. Intervention: The tacrolimus group received a vial containing tacrolimus 0.03% (almond oil as vehicle) and the other group received the almond oil vehicle. All patients were instructed to use the eye drops every 12 h in the lower conjunctival sac. Main outcome measures: Schirmer I test, break-up-time (BUT), corneal fluorescein and Rose Bengal staining scores were evaluated in all patients one day before the treatment (baseline), 7, 14, 28 and 90 days after treatment with the eye drops. Results: The average fluorescein and Rose Bengal scores improved statistically after 7 days of treatment and even more after 90 days. The average Schirmer I and BUT values were unchanged after 7, 14 and 21 days but did show an improvement relative to baseline after 28 days of treatment. Schirmer I, BUT, fluorescein and Rose Bengal did not show any statistical significance in the vehicle group. Conclusion: Topical 0.03% tacrolimus eye drop improved tear stability and ocular surface status in cases of inflammatory or SS-related dry eye. Trial registration: ClinicalTrials.gov Identifier: NCT01850979.
Palavras-chave
Keratoconjunctivitis sicca, Sjogren's syndrome, Tacrolimus
URI
https://observatorio.fm.usp.br/handle/OPI/12510
Referências
  1. KINO T, 1987, J ANTIBIOT, V40, P1256
  2. Izci C, 2002, AM J VET RES, V63, P688, DOI 10.2460/ajvr.2002.63.688
  3. Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554
  4. Berdoulay A, 2005, VET OPHTHALMOL, V8, P225, DOI 10.1111/j.1463-5224.2005.00390.x
  5. Moscovici BK, 2012, CORNEA, V31, P945, DOI 10.1097/ICO.0b013e31823f8c9b
  6. Lemp MA, 2007, OCUL SURF, V5, P75
  7. Aoki S, 2005, BRIT J OPHTHALMOL, V89, P243, DOI 10.1136/bjo.2004.051391
  8. Attas-Fox L, 2008, CURR EYE RES, V33, P545, DOI 10.1080/02713680802149115
  9. Bertelmann E, 2004, OPHTHALMOLOGICA, V218, P359, DOI 10.1159/000080937
  10. Birnbaum F, 2009, CORNEA, V28, P715
  11. Birnbaum F, 2008, CORNEA, V27, P488
  12. Bounous DI, 1998, ADV EXP MED BIOL, V438, P997
  13. Felberg Sergio, 2006, Arq Bras Oftalmol, V69, P959, DOI 10.1590/S0004-27492006000600032
  14. Dhaliwal JS, 2008, CORNEA, V27, P488, DOI 10.1097/ICO.0b013e3181606086
  15. Fei WL, 2008, J OCUL PHARMACOL TH, V24, P235, DOI 10.1089/jop.2007.0059
  16. Figueroa MS, 2007, EUR J OPHTHALMOL, V17, P69
  17. Fujita E, 2008, J OCUL PHARMACOL TH, V24, P309, DOI 10.1089/jop.2007.0083
  18. Fujita E, 2008, J OCUL PHARMACOL TH, V24, P333, DOI 10.1089/jop.2007.0086
  19. HIKITA N, 1995, CURR EYE RES, V14, P209, DOI 10.3109/02713689509033516
  20. Hikita N, 1997, INVEST OPHTH VIS SCI, V38, P901
  21. Hogan AC, 2007, OPHTHALMOLOGY, V114, P1000, DOI 10.1016/j.ophtha.2007.01.026
  22. Joseph MA, 2005, CORNEA, V24, P417, DOI 10.1097/01.ico.0000151507.49565.6e
  23. KAWASHIMA H, 1988, INVEST OPHTH VIS SCI, V29, P1265
  24. KINO T, 1987, J ANTIBIOT, V40, P1249
  25. KINO T, 1987, TRANSPLANT P, V19, P36
  26. Kymionis GD, 2008, CORNEA, V27, P228, DOI 10.1097/ICO.0b013e318159afbb
  27. Kymionis GD, 2004, CORNEA, V23, P828, DOI 10.1097/01.ico.0000127484.46584.f6
  28. MASAOKA T, 1991, TRANSPLANT P, V23, P3228
  29. Michel JL, 2006, ANN DERMATOL VENER, V133, P161, DOI 10.1016/S0151-9638(06)70869-9
  30. MORIMOTO T, 1989, TRANSPLANT P, V21, P1059
  31. Nishino K, 2002, GRAEF ARCH CLIN EXP, V240, P137, DOI 10.1007/s00417-001-0424-0
  32. Nivenius E, 2007, EYE, V21, P968, DOI 10.1038/sj.eye.6702367
  33. Ogawa Y, 2001, CORNEA, V20, P430, DOI 10.1097/00003226-200105000-00020
  34. Ohashi Y, 2010, J OCUL PHARMACOL TH, V26, P165, DOI 10.1089/jop.2009.0087
  35. PLEYER U, 1993, INVEST OPHTH VIS SCI, V34, P2737
  36. Reinhard T, 2002, KLIN MONATSBL AUGENH, V219, P125, DOI 10.1055/s-2002-26727
  37. Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P539, DOI 10.1067/mai.2002.121831
  38. Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P547, DOI 10.1067/mai.2002.121832
  39. Reitamo Sakari, 2002, Am J Clin Dermatol, V3, P381, DOI 10.2165/00128071-200203060-00002
  40. Rikkers SM, 2003, AM J OPHTHALMOL, V135, P297, DOI 10.1016/S0002-9394(02)01982-7
  41. Sasakawa Y, 2000, EUR J PHARMACOL, V403, P281, DOI 10.1016/S0014-2999(00)00592-6
  42. Sengoku T, 2003, CLIN EXP ALLERGY, V33, P1555, DOI 10.1046/j.1365-2222.2003.01698.x
  43. Shoji J, 2005, JPN J OPHTHALMOL, V49, P205, DOI 10.1007/s10384-004-0187-3
  44. TODA I, 1993, CORNEA, V12, P366, DOI 10.1097/00003226-199307000-00015
  45. VANBIJST.OP, 1969, ARCH OPHTHALMOL-CHIC, V82, P10

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC